Abstract: Novel compositions and methods of using the compositions to treat triple negative breast cancer are presented. 4-Ethyl-N-(7-hydroxy-3,4-dihydroisoquinolin-2(1H)-yl) benzamide has been shown to downregulate the expression of several genes associated with TNBC such as amphiregulin (AREG), epiregulin (EREG), inhibitor of DNA binding 1 (ID1), inhibitor of DNA binding 3 (ID3), killer cell lectin like receptor C3 (KLRC3), cyclooxygenase-2 (COX2), and intercellular adhesion molecule 1 (ICAM-1). In addition, the compound has been shown to downregulate the oncostatin M(OSM) signaling pathway.

Abstract: Disclosed herein is the use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetra-hydropyridine as a treatment for cancer.

Abstract: Disclosed herein is the use of N-(4-iodobenzoylamino)-5-ethyl-1,2,3,6-tetra-hydropyridine as a treatment for cancer.

Abstract: The compounds herein disclosed are N-substituted tetrahydroisoquinoline benzamide and benzene sulfonamide compounds that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-substituted tetrahydroisoquinoline compounds have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6- to 10-fold less than the IC50 of Tamoxifen.

Abstract: The compounds herein disclosed are tetrahydroisoquinoline analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of tetrahydroisoquinoline have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.

Abstract: The compounds herein disclosed are N-aminopyrrolylmethyltetrahydropyridine analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-aminopyrrolylmethyltetrahydropyridines have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.

Abstract: The compounds herein disclosed are N-aminopyrrolylmethyltetrahydropyridine analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of N-aminopyrrolylmethyltetrahydropyridines have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.

Abstract: The compounds herein disclosed are tetrahydroisoquinoline analogs that have modifications on the phenyl rings by introducing groups with various electronic properties. These derivatives of tetrahydroisoquinoline have been shown to have anti-proliferative activity against cells. In particular, the compounds have been found to be effective in inhibiting the proliferation of cancer cells, such as cancer cells that originated in breast tissue. Additionally, it has been shown that the novel compounds have IC50 values against the breast cancer cells that are 6-10-fold less than the IC50 of tamoxifen.

Abstract: The present invention relates to a process for the preparation of 2,6-divinylpyridine and 2-methyl-6-vinylpyridine over modified zeolite catalysts. In particular, it relates to the method for the synthesis of 2,6-divinylpyridine and 2-methyl-6-vinylpyridine from 2,6-lutidine and formaldehyde in vapour phase in an eco-friendly method with high yield and selectivity. This invention provides a non-corrosive, eco-friendly process, where the catalyst can be reused for many times. 2,6-Divinylpyridine is useful stating material in polymer industry.

Abstract: The present invention relates to a process for the preparation of 2,6-divinylpyridine and 2-methyl-6-vinylpyridine over modified zeolite catalysts. In particular, it relates to the method for the synthesis of 2,6-divinylpyridine and 2-methyl-6-vinylpyridine from 2,6-lutidine and formaldehyde in vapour phase in an eco-friendly method with high yield and selectivity. This invention provides a non-corrosive, eco-friendly process, where the catalyst can be reused for many times.